Pot Inc. is gearing up to lobby the Trump administration – and press its case that the president’s executive order declaring marijuana a drug useful for medical purposes is being thwarted by Wall Street, On The Money has learned.As reported by The Post, people at big banks – JPMorgan, Bank of America and Citigroup – have said the Trump executive order “reclassifying” pot from its previous heroin-like Schedule 1 level to a so-called Schedule 3 drug like Tylenol with codeine stops short of giving them the aut ...